Posted in | News | Nanofluidics | Nanobusiness

PositiveID’s Microfluidics-Based System Meets Key Requirements of BioWatch

PositiveID has achieved a key development in evaluating its Microfluidics-based Bioagent Autonomous Networked Detector (M-BAND) as part of its preparation to submit a proposal for the Department of Homeland Security's BioWatch procurement worth $3 billion.

PositiveID’s M-BAND system identifies five organisms mentioned in the CDC Select Agents List, a key prerequisite for BioWatch. The early warning system, M-BAND was developed by MFS for the Department of Homeland Security. It can detect the presence of aerosolized biological agents released deliberately.

The M-BAND system operates autonomously for up to one month between scheduled service cycles to constantly analyze air samples, particularly in high-traffic regions, for detecting toxins, viruses, and bacteria. It reports results within 3h. These results from each M-BAND system are sent in real time through a secure wireless network to present a precise and recent status of fielded devices collectively.

The M-BAND system delivers high operational flexibility. It can be remotely installed for the detection of either DNA-based pathogens alone or with or without either RNA-based toxins or organisms. It can also simultaneously detect all three kinds of pathogens at remotely programmable intervals. It offers various benefits over competitive products, including a small footprint, reduced operating costs and consumable, and a closed operating environment. It uses industry gold-standard TaqMan PCR chemistry for operation.

Besides bidding for BioWatch, PositiveID is also working on submitting proposals for over $16 million contract opportunities from six government agencies for its M-BAND and Dragonfly Rapid MDx Cartridge-based diagnostic system. PositiveID’s Chairman and Chief Executive Officer, William J. Caragol stated that the M-BAND system not only outperforms competitive products but also offers a comparatively lower cost of ownership.

Disclaimer: The views expressed here are those of the author expressed in their private capacity and do not necessarily represent the views of AZoM.com Limited T/A AZoNetwork the owner and operator of this website. This disclaimer forms part of the Terms and conditions of use of this website.

G.P. Thomas

Written by

G.P. Thomas

Gary graduated from the University of Manchester with a first-class honours degree in Geochemistry and a Masters in Earth Sciences. After working in the Australian mining industry, Gary decided to hang up his geology boots and turn his hand to writing. When he isn't developing topical and informative content, Gary can usually be found playing his beloved guitar, or watching Aston Villa FC snatch defeat from the jaws of victory.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Thomas, G.P.. (2019, February 12). PositiveID’s Microfluidics-Based System Meets Key Requirements of BioWatch. AZoNano. Retrieved on November 22, 2024 from https://www.azonano.com/news.aspx?newsID=24868.

  • MLA

    Thomas, G.P.. "PositiveID’s Microfluidics-Based System Meets Key Requirements of BioWatch". AZoNano. 22 November 2024. <https://www.azonano.com/news.aspx?newsID=24868>.

  • Chicago

    Thomas, G.P.. "PositiveID’s Microfluidics-Based System Meets Key Requirements of BioWatch". AZoNano. https://www.azonano.com/news.aspx?newsID=24868. (accessed November 22, 2024).

  • Harvard

    Thomas, G.P.. 2019. PositiveID’s Microfluidics-Based System Meets Key Requirements of BioWatch. AZoNano, viewed 22 November 2024, https://www.azonano.com/news.aspx?newsID=24868.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.